Latest research on Erlotinib

Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Erlotinib dosage

Concentrations of Erlotinib had been determined to be substantial enough to inhibit tumor cell proliferation in cerebrospinal fluid after an intravenous dose in healthy adult rhesus monkeys. [source, 2016]
Additional inclusion criteria for the Erlotinib group were the patients 1) in whom Erlotinib was administrated in first-line or second-line treatment (with cisplatin/pemetrexed or carboplatin/paclitaxel applied in first-line chemotherapy for at least two cycles); 2) in whom Erlotinib was orally administrated at a prescribed daily dose of 100–150 mg until any disease progression or intolerable toxicity was evaluated by qualified oncologists; 3) without any anti-EGFR therapy, other than Erlotinib, before the occurrence of BM; 4) in whom Erlotinib administration lasted for >2 months, followed by efficacy evaluation based on the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines16 obtaining Complete response (CR)/partial response (PR) or stable disease (SD). [source, 2016]
Two, 21 and 2 patients received afatinib 50 mg, 40 mg and 30 mg daily respectively while all patients in the Erlotinib group received Erlotinib at 150 mg daily as the starting dose. [source, 2016]
Several case reports suggest 26–29 that under conditions of severe hepatic dysfunction that cannot be treated with routine hepatoprotective treatment, switching to another EGFR-tyrosine kinase inhibitor such as Erlotinib or dose reduction of Gefitinib may be two possible choices. [source, 2016]
A total of 44 patients were enrolled and received at least one dose of bevacizumab plus Erlotinib and were included in the final analysis, they had the median follow-up time of 33.8 months (95% CI: 23.5 months – not defined). [source, 2016]
However, IL-6 inhibition with CNTO328 did not inhibit cell growth in HCC4006ER cells, even when combined with Erlotinib at clinically relevant dose ranges (S4 Fig). [source, 2016]
When SUM-149 cells were treated with Erl/GLE at doses greater than the IC50s of each, the cells were significantly sensitive compared with Erlotinib. [source, 2016]
These results suggest that a synergic effect occurs between Erlotinib and GLE at low and at high doses. [source, 2016]
Using non-lethal doses of Erlotinib or GLE we showed that Erl/GLE was more effective in decreasing IBC cell motility. [source, 2016]
In this study, we treated mice with a non-affecting tumor size GLE dose (unpublished data) in combination with Erlotinib. [source, 2016]